Identification of microRNAs involved in Alzheimer’s progression using a rabbit model of the disease

American Journal of Neurodegenerative Diseases

Volumn 3, Issue 1, 2014, Pages 33-44

  Liu, Qing Yan ^a,b   Chang, Marilyn N Vera ^b   Lei, Joy X ^a   Koukiekolo, Roger ^a   Smith, Brandon ^a   Zhang, Dongling ^a   Ghribi, Othman ^c  

^a NATIONAL RESEARCH COUNCIL CANADA   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

^c UNIVERSITY OF NORTH DAKOTA   (United States)

Author keywords

Alzheimer s disease; Leptin; Let 7; MicroRNA; MiR 26b; Rabbit AD model

Indexed keywords

LEPTIN; MICRORNA; MICRORNA 107; MICRORNA 125B; MICRORNA 15A; MICRORNA 16B; MICRORNA 30; MICRORNA 576 3P; MICRORNA 9; MICRORNA 98; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DOWN REGULATION; GENE EXPRESSION; MALE; MICROARRAY ANALYSIS; MOLECULAR PATHOLOGY; NERVE DEGENERATION; NONHUMAN; RABBIT; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ISOLATION; UPREGULATION;

EID: 84980052130     PISSN: None     EISSN: 2165591X     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Taylor JP, Hardy J and Fischbeck KH. Toxic proteins in neurodegenerative disease. Science 2002; 296: 1991-1995.
2. St George-Hyslop PH. Molecular genetics of Alzheimer disease. Semin Neurol 1999; 19: 371-383.
3. Selkoe DJ. Alzheimer's disease: genes, proteins, and therapy. Physiol Rev 2001; 81: 741-766.
4. Fan LY and Chiu MJ. Pharmacological treatment for Alzheimer's disease: current approaches and future strategies. Acta Neurol Taiwan 2010; 19: 228-245.
5. Golde TE, Schneider LS and Koo EH. Anti-abeta therapeutics in Alzheimer's disease: the need for a paradigm shift. Neuron 2011; 69: 203-213.
6. Sambamurti K, Greig NH, Utsuki T, Barnwell EL, Sharma E, Mazell C, Bhat NR, Kindy MS, Lahiri DK and Pappolla MA. Targets for AD treatment: conflicting messages from gamma-secretase inhibitors. J Neurochem 2011; 117: 359-374.
7. Miller LJ and Chacko R. The role of cholesterol and statins in Alzheimer's disease. Ann Pharmacother 2004; 38: 91-98.
8. Puglielli L, Tanzi RE and Kovacs DM. Alzheimer's disease: the cholesterol connection. Nat Neurosci 2003; 6: 345-351.
9. Wolozin B. A fluid connection: cholesterol and Abeta. Proc Natl Acad Sci U S A 2001; 98: 5371-5373.
10. Wolozin B. Cholesterol and the biology of Alzheimer's disease. Neuron 2004; 41: 7-10.
11. Ghribi O, Golovko MY, Larsen B, Schrag M and Murphy EJ. Deposition of iron and beta-amyloid plaques is associated with cortical cellular damage in rabbits fed with long-term cholesterol-enriched diets. J Neurochem 2006; 99: 438-449.
12. Ghribi O, Larsen B, Schrag M and Herman MM. High cholesterol content in neurons increases BACE, beta-amyloid, and phosphorylated tau levels in rabbit hippocampus. Exp Neurol 2006; 200: 460-467.
13. Ghribi O. Potential mechanisms linking cholesterol to Alzheimer's disease-like pathology in rabbit brain, hippocampal organotypic slices, and skeletal muscle. J Alzheimers Dis 2008; 15: 673-684.
14. Sparks DL. The early and ongoing experience with the cholesterol-fed rabbit as a model of Alzheimer's disease: the old, the new and the pilot. J Alzheimers Dis 2008; 15: 641-656.
15. Woodruff-Pak DS, Agelan A and Del VL. A rabbit model of Alzheimer's disease: valid at neuropathological, cognitive, and therapeutic levels. J Alzheimers Dis 2007; 11: 371-383.
16. Schreurs BG. Cholesterol and Copper Affect Learning and Memory in the Rabbit. Int J Alzheimers Dis 2013; 2013: 518780.
17. Valencia-Sanchez MA, Liu J, Hannon GJ and Parker R. Control of translation and mRNA degradation by miRNAs and siRNAs. Genes Dev 2006; 20: 515-524.
18. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116: 281-297.
19. Filipowicz W, Bhattacharyya SN and Sonenberg N. Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight? Nat Rev Genet 2008; 9: 102-114.
20. Friedman RC, Farh KK, Burge CB and Bartel DP. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res 2009; 19: 92-105.
21. Lewis BP, Burge CB and Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005; 120: 15-20.
22. Fineberg SK, Kosik KS and Davidson BL. MicroRNAs potentiate neural development. Neuron 2009; 64: 303-309.
23. Chan AW and Kocerha J. The Path to microRNA Therapeutics in Psychiatric and Neurodegenerative Disorders. Front Genet 2012; 3: 82.
24. Satoh J. Molecular network of microRNA targets in Alzheimer's disease brains. Exp Neurol 2012; 235: 436-446.
25. Nelson PT, Wang WX and Rajeev BW. MicroRNAs (miRNAs) in Neurodegenerative Diseases. Brain Pathol 2008; 18: 130-138.
26. Wang WX, Rajeev BW, Stromberg AJ, Ren N, Tang G, Huang Q, Rigoutsos I and Nelson PT. The expression of microRNA miR-107 decreases early in Alzheimer's disease and may accelerate disease progression through regulation of beta-site amyloid precursor protein-cleaving enzyme 1. J Neurosci 2008; 28: 1213-1223.
27. Schonrock N, Ke YD, Humphreys D, Staufenbiel M, Ittner LM, Preiss T and Gotz J. Neuronal microRNA deregulation in response to Alzheimer's disease amyloid-beta. PLoS One 2010; 5: e11070.
28. Wang X, Liu P, Zhu H, Xu Y, Ma C, Dai X, Huang L, Liu Y, Zhang L and Qin C. miR-34a, a microRNA up-regulated in a double transgenic mouse model of Alzheimer's disease, inhibits bcl2 translation. Brain Res Bull 2009; 80: 268-273.
29. Delay C and Hebert SS. MicroRNAs and Alzheimer's Disease Mouse Models: Current Insights and Future Research Avenues. Int J Alzheimers Dis 2011; 2011: 894938.
30. Li SC, Chan WC, Hu LY, Lai CH, Hsu CN and Lin WC. Identification of homologous microRNAs in 56 animal genomes. Genomics 2010; 96: 1-9.
31. Liu G, Fang Y, Zhang H, Li Y, Li X, Yu J and Wang X. Computational identification and microarray-based validation of microRNAs in Oryctolagus cuniculus. Mol Biol Rep 2010; 37: 3575-3581.
32. Cogswell JP, Ward J, Taylor IA, Waters M, Shi Y, Cannon B, Kelnar K, Kemppainen J, Brown D, Chen C, Prinjha RK, Richardson JC, Saunders AM, Roses AD and Richards CA. Identification of miRNA changes in Alzheimer's disease brain and CSF yields putative biomarkers and insights into disease pathways. J Alzheimers Dis 2008; 14: 27-41.
33. Wang WX, Huang Q, Hu Y, Stromberg AJ and Nelson PT. Patterns of microRNA expression in normal and early Alzheimer's disease human temporal cortex: white matter versus gray matter. Acta Neuropathol 2011; 121: 193-205.
34. Lukiw WJ. Micro-RNA speciation in fetal, adult and Alzheimer's disease hippocampus. Neuroreport 2007; 18: 297-300.
35. Hebert SS, Horre K, Nicolai L, Papadopoulou AS, Mandemakers W, Silahtaroglu AN, Kauppinen S, Delacourte A and De SB. Loss of microRNA cluster miR-29a/b-1 in sporadic Alzheimer's disease correlates with increased BACE1/beta-secretase expression. Proc Natl Acad Sci U S A 2008; 105: 6415-6420.
36. Nelson PT and Wang WX. MiR-107 is reduced in Alzheimer's disease brain neocortex: validation study. J Alzheimers Dis 2010; 21: 75-79.
37. Yao J, Hennessey T, Flynt A, Lai E, Beal MF and Lin MT. MicroRNA-related cofilin abnormality in Alzheimer's disease. PLoS One 2010; 5: e15546.
38. Wilfred BR, Wang WX and Nelson PT. Energizing miRNA research: a review of the role of miRNAs in lipid metabolism, with a prediction that miR-103/107 regulates human metabolic pathways. Mol Genet Metab 2007; 91: 209-217.
39. Xu G, Ji C, Shi C, Fu H, Zhu L, Zhu L, Xu L, Chen L, Feng Y, Zhao Y, Guo X. Modulation of hsa-miR-26b levels following adipokine stimulation. Mol Biol Rep 2013; 40: 3577-3582.
40. Marwarha G, Dasari B, Prasanthi JR, Schommer J and Ghribi O. Leptin reduces the accumulation of Abeta and phosphorylated tau induced by 27-hydroxycholesterol in rabbit organotypic slices. J Alzheimers Dis 2010; 19: 1007-1019.
41. Chen PS, Su JL, Cha ST, Tarn WY, Wang MY, Hsu HC, Lin MT, Chu CY, Hua KT, Chen CN, Kuo TC, Chang KJ, Hsiao M, Chang YW, Chen JS, Yang PC and Kuo ML. miR-107 promotes tumor progression by targeting the let-7 microRNA in mice and humans. J Clin Invest 2011; 121: 3442-3455.